STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Oncocyte Corp (Nasdaq: OCX), a diagnostics technology company, has announced its participation in 'J.P. Morgan Week' alongside the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.

CEO Josh Riggs and CFO Andrea James will be available for one-on-one meetings with investors during the event. Interested investors can schedule meetings through Julie Silber at PCG Advisory.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

January 13-16, 2025, San Francisco, CA

IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors.

Investors wishing to schedule a meeting are encouraged to contact Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.

Event: “J.P. Morgan Week”
Dates: January 13-16, 2025
Location: San Francisco, CA, USA

About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney™ – https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ – https://oncocyte.com/vitagraft-liver/
GraftAssure™ – https://oncocyte.com/graftassure/
DetermaIO™ – https://oncocyte.com/determa-io/
DetermaCNI™ – https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com


FAQ

When is Oncocyte (OCX) participating in JP Morgan Week 2025?

Oncocyte (OCX) will participate in JP Morgan Week from January 13-16, 2025, in San Francisco.

Who will represent Oncocyte (OCX) at JP Morgan Week 2025?

CEO Josh Riggs and CFO Andrea James will represent Oncocyte (OCX) at JP Morgan Week 2025.

How can investors schedule meetings with Oncocyte (OCX) during JP Morgan Week 2025?

Investors can schedule meetings by contacting Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.

Where will Oncocyte (OCX) host investor meetings during JP Morgan Week 2025?

Oncocyte (OCX) will host investor meetings in San Francisco during JP Morgan Week 2025.
Oncocyte Corporation

NASDAQ:OCX

OCX Rankings

OCX Latest News

OCX Latest SEC Filings

OCX Stock Data

77.22M
22.30M
In-Vitro Diagnostic Substance Manufacturing
In Vitro & in Vivo Diagnostic Substances
Link
US
IRVINE